Bleeding disorders Flashcards

1
Q

Haemophilia types?

A

A and B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Haemophilia type A

A

Defect in F8 gene causing reduced FVIII (haemophilia A)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Haemophilia type B

A

Defect in F9 gene causing reduced FIX (haemophilia B)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Haemophilia genetics

A

Sex-linked recessive inheritance (on X chromosome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Sx of Haemophilia

A

Coagulation pathway disorder

  • Mild or severe bleeding depending on factor level (Soft tissue and joint, CNS, GI bleeds)
  • Chronic arthropathy (bleeding in joint leads to inflammation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mx of haemophilia

A
  • Recombinant factor concentrate (synthetic factor 8 & 9)
  • prophylaxis every 2-3 weeks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

normal roles of vwf?

A
  • VWF mediates PLT adhesion to collagen

- stabilises coagulation Factor VIII in the plasma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Mild Von Willebrand disease cause

A
  • Defective primary haemostasis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Mild Von Willebrand disease sx

A
  • Epistaxis
  • easy bruising
  • traumatic skin bleeding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Severe Von Willebrand disease cause

A
  • Additional coagulation pathway

- defect due to low FVIII

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Von Willebrand disease tests?

A
  • Long aPTT in moderate or severe VWD (when FVIII level is low)
  • reduced plasma VWF activity
  • reduced plasma FVIII activity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Management of VWD?

A

I. Tranexamic acid
II. DDAVP/Desmopressin
III. VWF/FVIII concentrate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Tranexamic acid

A

Reduces clot break-down

antifibrinolytic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

DDAVP/Desmopressin

A
  • Releases endogenous FVIII and VWF

- only works once, temporary release

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Bleeding disorders acquired causes

A
  1. Abnormal synthesis
  2. Abnormal function
  3. Dilution
  4. Consumption
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Potential causes of abnormal synthesis leading to acquired bleeding disorders?

A
  • Liver disease
  • Vitamin K deficiency (coagulation factors II, VII, IX, X)
  • Warfarin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Potential causes of abnormal function leading to acquired bleeding disorders?

A
  • Heparin and direct acting oral anticoagulants*
  • Renal failure (platelet dysfunction)
  • Anti-platelet drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Potential causes of dilution leading to acquired bleeding disorders?

A
  • Massive transfusion

* Cardiopulmonary bypass

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Potential causes of consumption leading to acquired bleeding disorders?

A

(Thrombotic microangiopathies )
• Disseminated intravascular coagulation*
• Thrombocytopenia in sepsis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Liver damage and clotting?

A

I. ↓Synthesis of most clotting factors, fibrinogen and coagulation regulators
II. ↓PLT number
III. Biliary obstruction gives vit K malabsorption
IV. Hyperfibrinolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Vit K role?

A

needed for synthesis of Factors II, VII, IX and X

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Disseminated intravascular coagulation (DIC) causes

A
I. Sepsis
II. Major trauma
III. Obstetric emergencies (pre-eclampsia,
amniotic fluid embolism, retained POC)
IV. Advanced malignancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Disseminated intravascular coagulation (DIC) pathophysiology

A

I. Pro-coagulant stimulus + loss of regulatory pathways –> Widespread activation of coagulation pathway

II. Fibrin/platelet rich
microvascular thrombi and Multiorgan failure

III. Platelet, fibrinogen and
coag factor consumption and bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Management of DIC

A

• Fresh frozen plasma
• Platelet transfusion
• Fibrinogen concentrate or
cryoprecipitate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Thrombotic thrombocytopenic purpura (TTP) Sx?
- onset fever, malaise, arthralgia - Bleeding • Variable neurological features • Chest pain • Jaundice + abdo pain
26
Thrombotic thrombocytopenic purpura (TTP) cause?
Caused by anti-ADAMTS13 antibodies
27
Thrombotic thrombocytopenic purpura (TTP) pathology?
anti-ADAMTS13 antibodies-> Reduced proteolysis of VWF -> Circulating ultra-high molecular weight VWF multimers -> Platelet agglutination in ‘high shear’ vessels, microvascular, thrombosis, platelet consumption, mechanical haemolysis
28
Diagnosis of TTP
Blood film is diagnostic: smashed in half | PLT reduced and Hb reduced
29
Mx of TTP?
``` PLASMA EXCHANGE or II. Supportive care • RBC transfusion • Aspirin and LMW heparin • Iv corticosteroids Rituximab ```
30
DVT 1. first investigation? 2. secondary Ix?
1. Wells score for DVT diagnosis 2. I. Score >1= - DVT likely - Doppler USS II. Score 1 or less: - DVT unlikely - D dimer test - Doppler USS if high
31
DVT complications?
Post-thrombotic syndrome: - Chronic swelling and aching - Venous eczema and ulcers
32
PE complication?
``` Chronic thromboembolic pulmonary hypertension (CTPH) ``` - 0.5-5% of treated clots replaced by fibrous tissue - Progressive Pulmonary HTN and RHF
33
3 conditions that increase the risk of DVT?
1. Antithrombin deficiency 2. Factor V Leiden 3. antiphospholipid syndrome
34
Antithrombin deficiency mx
- Long term anticoagulation - short term AT concentrate
35
Factor V Leiden pathology?
Reduces inactivation of Factor V by activated protein C
36
Management of anti phospholipid syndrome?
- If thrombotic, long term anticoagulation (plus antiplatelet agent if arterial thrombosis)
37
Immediate Management of DVT and PE?
- Fast acting anticoagulant minimum 3 months | - (Rivaroxaban or LMW heparin)
38
long term Management of DVT and PE?
anticoagulation: - Rivaroxaban, - warfarin. - LMWH in cancer or pregnancy
39
2 types of Anti-thrombotic drugs
1. Anti-platelet drugs | 2. Anti-coagulant drugs
40
Anti platelet drugs used for?
Treatment/prevention arterial thrombosis | eg ACS
41
Anti coagulant drugs used for?
treatment/prevention venous thrombosis or low pressure vessel thrombosis eg DVT, PE, CVA in AF
42
NICE guidlines for VTE thromboprophylaxis
All patients at risk of VTE should: • Mobilise early • Receive pharmaceutical thromboprophylaxis (eg enoxaparin 40 mg once daily)
43
mech of action of heparin
• Increases activity of natural anticoagulant antithrombin • Inhibits active clotting factors esp. Factors IIa (thrombin) and Xa
44
Route of UF heparin
IV
45
Route of LMW heparin
SC
46
Metabolism of UF heparin
Renal
47
Metabolism of LMW heparin
Renal
48
Half life of UF heparin
1-2hours
49
Half life of LMW heparin
4-6 hours
50
Reversal of UF heparin
Protamine iv 1mg/100 IU heparin in last hr (max 40mg)
51
Reversal of LMW heparin
Protamine iv 1mg/100 IU heparin in last hr (max 40mg)
52
Direct oral anticoagulant (DOAC) example?
rivaroxaban
53
Rivaroxaban mech of action
* Factor Xa inhibitor | * Reduces thrombin generation
54
Rivaroxaban use?
I. VTE prevention after knee/hip replacement II. Stroke prevention in non-valvular AF III. Acute and long term treatment of DVT
55
Rivaroxaban half life?
8 hours
56
Rivaroxaban metabolised by
75% liver metabolised, | 25% renal excreted
57
Rivaroxaban reversal?
Specialist products (APCC, specific reversal agents) for severe bleeding
58
Warfarin mech of action?
Inhibits vitamin K metabolism (factors 2,7,9,10)
59
Warfarin uses?
I. when DOACs are unsafe II. Long term VTE III. Stroke prevention in AF IV. With anti-platelet agent, to prevent arterial thrombosis
60
when are DOACs unsafe
- Mechanical heart valves, - Antiphosphoilipid syndrome, - CKD
61
Warfarin half life
Plasma half life ~36 hours
62
Warfarin metabolised by
liver
63
Warfarin reversal
- Vitamin K if INR >8.0 for mild bleeding | - Vitamin K factor concentrate (eg Octaplex) plus Vit K for severe bleeding